Sep 2026· Current Reviews in Clinical and Experimental Pharmacology· Vol 21· 0 citations
Medicine
TL;DR
A greater international regulatory harmonization, stronger quality assurance frameworks, and evidence-based monitoring systems are required for cannabinoids and cannabis products, crucial for protecting public health, supporting scientific research, and enabling the responsible integration of cannabinoid-based therapies into modern healthcare systems.
Abstract
INTRODUCTION
Over the last decade, the regulation of cannabinoids and cannabis-based medicinal products has undergone significant transformation, determined by growing evidence of their therapeutic value and increasing concerns about safety, misuse, and product diversion. The objective of this review was to examine current regulatory frameworks across major jurisdictions from a public health policy perspective, highlighting how different approaches seek to balance patient access with health protection.
Methods
This review followed a targeted literature search in scientific databased (PubMed and Google Scholar) to identify publications in English language addressing the evolution of medical cannabis and cannabinoid policies, with particular emphasis on the regulatory frameworks in various countries. The identified literature was qualitatively analyzed to evaluate the relationship between international policy developments and the evolution of national medical cannabis regulations and research activities.
Results
This review identified three primary regulatory models: traditional pharmaceutical approval pathways that require robust clinical evidence; alternative access mechanisms, e.g., compassionate- use and special access programs; and regulatory systems which have varying levels of regulatory oversight, quality control, and patient protections, especially the vulnerable population.
Discussion
While there has been an increasing global acceptance of cannabinoid-based therapies, considerable differences in regulatory requirements remain across countries. Such a fragmentation creates barriers to clinical research on cannabinoids and cannabis products, obscures patient access, and limits effective public health surveillance. Additionally, challenges related to product quality, standardization, labeling accuracy, and pharmacovigilance are particularly obvious for botanical cannabis products, where regulatory expectations often differ from those applied to conventional medicines. At the same time, innovative regulatory developments are emerging.
Conclusion
The review highlights that a greater international regulatory harmonization, stronger quality assurance frameworks, and evidence-based monitoring systems are required for cannabinoids and cannabis products. These aspects are crucial for protecting public health, supporting scientific research, and enabling the responsible integration of cannabinoid-based therapies into modern healthcare systems.
Objective: To review the pharmacological, clinical, and regulatory principles governing the medical use of cannabinoids in Brazil, with emphasis on pharmaceutical-grade products currently authorized for sale in Brazilian pharmacies. Methods: This narrative review synthesized literature published between 2015 and 2025...
Pedro d'Elia Machado Silva, Maria Clara Martins de Souza, Cassiano Teixeira· Revista de Geopolítica· 0 citations
The legalisation of medicinal cannabis has increasingly shifted the regulatory debate from whether cannabis should be permitted for medical purposes to how effective governance can ensure safe, equitable and meaningful patient access. Although Australia and the United Kingdom have established legal pathways for medicin...
Ekmil Krisnawati Erlen Joni, Ida Rahayu Mahat, P. Musa· International journal of res...· 0 citations
Cannabis sativa is commonly known as cannabis or marijuana. It is a psychoactive drug. It has been in use for thousands of years for its medicinal and recreational properties. This article explores the regulatory frameworks governing cannabis and similar drugs in the United States (US), India, and Australia, highlighti...
A. Singh, V. K. Shukla, Navneet Sharma· Journal of Opioid Management· 0 citations
Cannabis and cannabinoid-based products are increasingly used by people with cancer, yet the term “cancer treatment” encompasses two fundamentally different questions: whether cannabinoids can relieve cancer- or treatment-related symptoms, and whether they can modify tumour biology sufficiently to function as anticance...
B. G. Ibokette, Uyoyou Winners Efi, Efe Oni et al.· Journal of Advances in Medic...· 0 citations
AIMS
This study aimed to clarify the pharmacological meaning of intoxication as it applies to cannabis-based medicines; distinguish intoxication from related terms such as psychoactive, psychotropic and euphorigenic; and evaluate how these distinctions inform clinical practice, prescribing frameworks and regulatory cla...
Martin Woodbridge, Juergen Fleisch· British Journal of Clinical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.